Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) to Post -$0.02 Earnings Per Share

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN) to report ($0.02) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Alpine Immune Sciences’ earnings. The lowest EPS estimate is ($0.52) and the highest is $1.51. Alpine Immune Sciences posted earnings of ($0.28) per share in the same quarter last year, which would indicate a positive year over year growth rate of 92.9%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 11th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.96) to $0.21. For the next year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.28) to $0.73. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, August 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.17). Alpine Immune Sciences had a negative net margin of 190.22% and a negative return on equity of 60.24%. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $6.59 million.

ALPN has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Alpine Immune Sciences in a research report on Thursday, June 24th. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, August 18th.

In related news, CEO Mitchell Gold sold 3,484 shares of Alpine Immune Sciences stock in a transaction dated Wednesday, September 15th. The stock was sold at an average price of $10.00, for a total value of $34,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 16,436 shares of company stock valued at $164,455. Corporate insiders own 57.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Alpine Immune Sciences by 1,933.8% during the 2nd quarter. BlackRock Inc. now owns 544,155 shares of the biotechnology company’s stock worth $4,898,000 after acquiring an additional 517,399 shares in the last quarter. Ikarian Capital LLC grew its stake in Alpine Immune Sciences by 6,330.4% during the 1st quarter. Ikarian Capital LLC now owns 304,739 shares of the biotechnology company’s stock worth $3,230,000 after buying an additional 300,000 shares during the last quarter. State Street Corp purchased a new position in Alpine Immune Sciences during the 2nd quarter worth approximately $1,558,000. Opaleye Management Inc. purchased a new position in shares of Alpine Immune Sciences in the 1st quarter valued at approximately $1,659,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Alpine Immune Sciences in the 2nd quarter valued at approximately $1,382,000. 55.07% of the stock is owned by hedge funds and other institutional investors.

Shares of Alpine Immune Sciences stock opened at $10.00 on Friday. The company has a market cap of $239.15 million, a PE ratio of -6.85 and a beta of 1.65. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average of $9.03 and a 200-day moving average of $10.36. Alpine Immune Sciences has a 1-year low of $7.21 and a 1-year high of $16.37.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies.

Featured Story: What is the Beige Book?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.